Read more
The series
Stem Cell Innovation in Health and Disease is a timely and fascinating collection of information and new discoveries and provides a contemporary snapshot album from the fast-moving field of regenerative medicine and stem cell therapeutics.
The Cardiovascular System:
From Bench to Bedside, Volume 6 addresses the recent data accumulated on the potential applications of stem cells to treat diseases and disorders of the cardiovascular system. This volume will highlight the recent development of cutting edge in vitro and in vivo research tools and approaches, including human and murine organoid cultures, genetic editing in vitro and in vivo, human iPSC models of disease, haploid cells for genetic as well as compoundscreening paradigms, genetically engineered mice, and stem cell transplantation to treat cardiovascular system disorders and diseases. The volume is written for researchers and scientists in stem celltherapy, cell biology, regenerative medicine and organ transplantation; and is contributed by world-renowned authors in the field.
List of contents
1. Stem Cell-based Cardiac Organoid Culture System
2. Innovated Therapeutic Gene Editing Technologies in Stem Cell Engineering and Cardiovascular Disorders and Diseases
3. Role of Genetically Modified Animal Models in Cardiovascular Diseases and Disorders
4. Advanced in Stem Cell-based Therapy of Cariovascular Diseases and Disorders
5. Derivation and Application of Embryonic Stem Cells as a Model for Heart Development Diseases and Disorders
6. Mesenchymal Stem Cell Related Therapies for Cardiovascular Diseases and Disorders
7. The Gold Standard iPSC-derived Cells and Technology in Modeling Cardiovascular Diseases and Disorders
8. Conclusion and Future Direction
About the author
Hussein Sabit graduated from Ain Shams University, Cairo and received his BSc in Genetics, where he also get his MSc in Microbial Genetics and PhD in Molecular Genetics. He joined Misr University for Science and Technology, Egypt as TA, Assistant Professor. Has been promoted to Associate Professor of Molecular Genetics, and Full Professor in Cancer Epigenetics. His research interest is Cancer Genetic/Epigenetic basis of carcinogenesis, genome editing via CRISPR/Cas9, studying the anti-apoptotic genes and its relations with BC progression, investigating the DNA methylation levels controlling carcinogenesis of BC, studying the chromatin remodelling as a main mechanisms leading to cancer using ChIP assays and others. He published 28 articles; most of them is the main field of Cancer Genetics/Epigenetics. He is the director of Cancer Epigenetics Research Unit (CERU) at MUST, where he leads a research team of postgrad students.
